Serum Carcinoembryonic Antigen Levels Before the First Curative Hepatectomy for Metastatic Colorectal Cancer Is a Predictor of Recurrence

Kawahara, Hidejiro; Yoshida, Seiya; Tohyama, Yoichi; Yanagisawa, Satoru; Misawa, Takeyuki; Yanaga, Katsuhiko

doi:10.21873/anticanres.12863

Cited by 6 publications

(6 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 36 studies were included, involving 11 143 subjects, composed of 6769 men and 4374 women. Of these studies, 19 were from Asia (Sasaki et al , 2005; Tanaka et al , 2008; Yi et al ., 2013; Lu et al ., 2016; Okimoto et al ., 2017; Peng et al ., 2017; Wang et al ., 2017; Zhang et al ., 2017; Kawahara et al , 2018; Miki et al ., 2018; Chiang et al ., 2019; Kim et al ., 2019; Chen et al ., 2020; Meng et al , 2021; Ishii et al ., 2022; Takamizawa et al ., 2022; Takeda et al ., 2022; Yoshino et al ., 2022; Li et al ., 2023), 11 from Europe (Hohenberger et al , 1994; Gervaz et al , 2000; Pawlik et al ., 2005; Arru et al ., 2008; John et al ., 2013; Montalti et al ., 2015; Hof et al , 2016; Imai et al ., 2016; Peltonen et al , 2018; Polivka et al ., 2020; Kamphues et al ., 2021), 4 from North America (Reddy et al , 2009a,b; Sasaki et al ., 2016; Masuda et al ., 2018), and one study each from Oceania (Niu et al , 2007) and South America (Dumarco et al ., 2023). A total of 31 studies discussed pre-LR CEA levels, and 9 studies investigated the effect of post-LR CEA levels on prognosis in CRCLM patients.…”

Section: Resultsmentioning

confidence: 99%

“…A total of 8 studies (Montalti et al ., 2015; Peng et al ., 2017; Wang et al ., 2017; Kawahara et al , 2018; Ishii et al ., 2022; Takamizawa et al ., 2022; Yoshino et al ., 2022; Li et al ., 2023) reported pre-LR serum CEA levels to predict RFS in patients. The heterogeneity test results showed I 2 = 37.9%, so a fixed-effects model was used for analysis.…”

Section: Resultsmentioning

confidence: 99%

“…Of these 36 studies we included, a total of 28 studies (Hohenberger et al, 1994;Pawlik et al, 2005;Sasaki et al, 2005;Arru et al, 2008;Tanaka et al, 2008;Reddy et al, 2009a,b;John et al, 2013;Montalti et al, 2015;Lu et al, 2016;Okimoto et al, 2017;Peng et al, 2017;Wang et al, 2017;Zhang et al, 2017;Masuda et al, 2018;Peltonen et al, 2018;Kim et al, 2019;Chen et al, 2020;Polivka et al, 2020;Kamphues et al, 2021;Meng et al, 2021;Ishii et al, 2022;Takamizawa et al, 2022;Takeda et al, 2022;Dumarco et al, 2023;Li et al, 2023) reported pre-LR serum CEA levels to predict OS in patients, 4 studies (Miki et al, 2018;Peltonen et al, 2018;Polivka et al, 2020;Dumarco et al, 2023) reported to predict DFS in patients, 8 studies (Montalti et al, 2015;Peng et al, 2017;Wang et al, 2017;Kawahara et al, 2018;Ishii et al, 2022;Takamizawa et al, 2022;Yoshino et al, 2022;Li et al, 2023) reported predicting patient RFS. A total of 8 studies (Hohenberger et al, 1994;Gervaz et al, 2000;…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Meta-analysis of the prognostic value of serum carcinoembryonic antigen in patients with colorectal cancer liver metastases after hepatectomy

Yuan,

Zeng,

Duan

et al. 2023

European Journal of Cancer Prevention

View full text Add to dashboard Cite

Objectives Carcinoembryonic antigen (CEA) is a broad-spectrum tumor marker for differential diagnosis, monitoring, and response assessment of a variety of malignancies. This meta-analysis was aimed at evaluating whether serum CEA could predict the prognosis in patients with colorectal cancer liver metastasis (CRCLM) before and after liver resection (LR). Methods PubMed, Embase, Cochrane, and Web of Science were systematically searched to retrieve literature, with a search cutoff date of 27 February 2023. Articles were strictly screened for inclusion according to pre-specified inclusion and exclusion criteria. Data were pooled and analyzed using Stata 16.0. Results This meta-analysis included 36 studies involving a total of 11 143 CRCLM patients. The results showed that a high pre-LR serum CEA level was correlated with poor overall survival (OS: HR = 1.61, 95% CI = 1.49–1.75, P < 0.001) and recurrence-free survival (RFS: HR = 1.27, 95% CI = 1.11–1.45, P < 0.001) in CRCLM patients. A high post-LR serum CEA level predicted poor overall survival (OS: HR = 2.66, 95% CI = 2.10–3.38, P < 0.001). Conclusion High preoperative and postoperative serum CEA levels in patients with CRCLM were significantly associated with poor prognosis, independent of treatment modality, mode of analysis, case origin, and cutoff value classification.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Meta-analysis of the prognostic value of serum carcinoembryonic antigen in patients with colorectal cancer liver metastases after hepatectomy

Yuan,

Zeng,

Duan

et al. 2023

European Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…There were several previous studies on the association between elevated serum levels of these markers and distant organ metastases (28)(29)(30). According to these reports, elevated levels of these markers might be considered an early warning sign in patients needing accurate imaging, as they are at higher risk of bone metastasis (28), liver metastasis (29), and several-organ metastases (30). Molecular biology studies show that CEA has a mechanism for distant organ metastasis via adhesive molecules (31).…”

Section: Discussionmentioning

confidence: 99%

Serum CEA and CYFRA Levels in ALK-rearranged NSCLC Patients: Correlation With Distant Metastasis

Numata

Endo

Yanai

et al. 2020

In Vivo

View full text Add to dashboard Cite

Aim: To clarify the correlation between serum levels of carcinoembryonic antigen (CEA) and cytokeratin 19 fragment (CYFRA) and metastasis and survival in anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) patients. Patients and Methods: CEA and CYFRA levels in 131 ALK-rearranged NSCLC patients were determined using fluorescence in situ hybridization (FISH), real time-reverse transcription polymerase chain reaction, and immunohistochemistry, using biopsy specimens, cytology specimens, and plasma specimens. Cutoff value of each marker was determined as 10 ng/ml. Results: In logistic regression analysis, higher levels of both markers had a positive relationship with bone metastases, and higher levels of CYFRA was relevant to liver metastases, and multiple-organ metastases. However, these markers were not proven to be poor prognostic factors in Cox's proportional model analysis. Conclusion: Elevated serum CEA and CYFRA levels seem to provide useful clinical information about presence of bone and liver metastasis and multiple-organ metastases, although they were not a powerful indicator of prognosis. These two markers may suggest the extension of metastasis and would be helpful in considering treatment options. Carcinoembryonic antigen (CEA) has been widely used in clinical practice as a serum tumor marker for non-small cell lung cancer (NSCLC) patients (1). Cytokeratin 19 fragment (CYFRA) is also one of the representative serum tumor markers used for detection of NSCLC patients in clinical practice (1). CEA is a glycoprotein and CYFRA is a soluble 2095 This article is freely accessible online.

show abstract

“…There are various risk clinicopathological factors that have been associated with poor prognosis, such as poorly differentiated primary tumours, metastatic tumour size over 5 cm, positive resection margins, and high preoperative carcinoembryonic antigen (CEA) levels [12][13][14][15] . Distant metastasis is mainly caused by a variety of gene mutations, and the epidermal growth factor receptor (EGFR) signalling pathway activated by KRAS mutation has been found to be crucial for CRC progression and metastasis [16][17][18][19] .…”

Section: Introductionmentioning

confidence: 99%

Association of RAS mutations with early progression after first-line systemic therapy in patients with initially unresectable colorectal cancer liver metastasis

Cao

Liu

Zhou

et al. 2021

Preprint

View full text Add to dashboard Cite

Purpose Patients with initially unresectable colorectal cancer with liver metastases (IU-CRLM) need to undergo first-line systemic therapy with the aid of chemotherapy. However, the driver gene attributed to early progression in IU-CRLM patients after first-line systemic therapy remains unclear. Our study explored the RAS mutation status related to early progression in IU-CRLM patients. Methods A total of 193 IU-CRLM patients with RAS status detection were retrospectively enrolled from December 2012 to January 2020. We defined early progression as tumour progression within 6 months after first-line systemic therapy. Univariate and multivariate logistic regression for early progression were implemented to identify the risk factors. Results RAS mutations were found in 51 (26.0%) IU-CRLM patients. A total of 107 (55.4%) patients were confirmed to have early progression after first-line systemic therapy. RAS mutation was significantly related to early disease progression (66.7% vs. 49.3%, P=0.033). Logistic analysis results showed that RAS mutation (OR=2.962, 95% CI 1.354-6.478, P=0.007) was an independent risk factor for early disease progression. Conclusions Mutated RAS was an important risk factor for early progression in IU-CRLM patients after first-line systemic therapy.

show abstract

Serum Carcinoembryonic Antigen Levels Before the First Curative Hepatectomy for Metastatic Colorectal Cancer Is a Predictor of Recurrence

Abstract: Serum CEA levels before the first curative hepatectomy for metastatic colorectal cancer seem to be a predictor of recurrence.

Cited by 6 publications

References 15 publications

Meta-analysis of the prognostic value of serum carcinoembryonic antigen in patients with colorectal cancer liver metastases after hepatectomy

Meta-analysis of the prognostic value of serum carcinoembryonic antigen in patients with colorectal cancer liver metastases after hepatectomy

Serum CEA and CYFRA Levels in ALK-rearranged NSCLC Patients: Correlation With Distant Metastasis

Association of RAS mutations with early progression after first-line systemic therapy in patients with initially unresectable colorectal cancer liver metastasis

Contact Info

Product

Resources

About